No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Emergent BioSolutions Inc. is a life sciences enterprise dedicated to developing and delivering solutions for preparing for and responding to diverse public health threats (PHTs) in the United States. Its mission involves countering unforeseen, intentional, and naturally arising health crises affecting populations. The company's product portfolio addresses a wide spectrum of PHTs, encompassing chemical, biological, radiological, nuclear, and explosive agents (CBRNE), emergent infectious diseases, travel-related health concerns, and immediate emergency medical needs. Among its key commercialized offerings are: Vaccines: BioThrax (for anthrax), ACAM2000 (for smallpox), Vivotif (an oral immunization against typhoid fever), and Vaxchora (a single-dose oral vaccine for cholera). Treatments & Antidotes: Botulism Antitoxin Heptavalent (combats botulism), vaccinia immune globulin intravenous (manages adverse reactions to smallpox vaccination), raxibacumab and Anthrasil (both for treating and preventing inhalational anthrax), and NARCAN (a nasal spray for immediate intervention in known or suspected opioid overdoses). Other Emergency Preparedness: Reactive skin decontamination lotion kits, and Trobigard, an investigational auto-injector product combining both drug and device components. Furthermore, Emergent BioSolutions boasts an active development pipeline, featuring candidates such as AP003 (a multidose Naloxone nasal spray), AP007 (a sustained-release Nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus-like particle vaccine), COVID-HIG (a treatment for SARS-CoV2), EGRD-001 (a diazepam auto-injector), SIAN (an antidote for acute cyanide poisoning), and UniFlu (a universal influenza vaccine). Beyond its proprietary products, the company also provides comprehensive contract development and manufacturing (CDMO) services. These services include drug substance and product manufacturing, packaging solutions, alongside specialized expertise in technology transfer, process optimization, and analytical development. Established in 1998, Emergent BioSolutions maintains its corporate headquarters in Gaithersburg, Maryland.
www.emergentbiosolutions.comNo one on the platform currently holds 0IGA.L.
No tracked institution reports a position in 0IGA.L as of their last filing.
No one on the platform has traded 0IGA.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.6% | — | — | — | ||
| Rev. Growth % | -28.8% | -13.7% | ||||
| Profit Margin % | 7.1% | -18.0% | -3.2% | |||
| Free Cash Flow Margin % | 21.1% | -6.0% | 2.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $657M | -18.8% | $0.36 | $0.32–$0.40 | — | 1 |
| 2027 | $703M | +7.0% | $1.05 | $0.93–$1.16 | — | 1 |
| 2028 | $628M | -10.7% | $1.57 | $1.39–$1.74 | — | 1 |
| 2029 | $963M | +53.3% | $0.90 | $0.80–$1.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.09 | $0.60 | +805.9% |
| 2026-04-30 | $-0.25 | $0.21 | +184.0% |
| 2026-02-26 | $0.11 | $-0.43 | -490.9% |
| 2025-10-29 | $-0.12 | $1.06 | +983.3% |
| 2025-08-06 | $-0.49 | $0.16 | +132.7% |
| 2025-05-07 | $0.44 | $0.71 | +61.4% |
| 2025-03-03 | $-0.50 | $0.05 | +109.9% |
| 2024-11-06 | $0.10 |
| $1.37 |
| +1226.2% |
| +3.48% |
| $259M |
| — |
| 0IIM.LEsperion Therapeutics, Inc. | $3.19 | +0.14% | $707M | — |
| 0IV3.LGeron Corporation | $1.31 | +0.49% | $879M | — |
Source: Financial Modeling Prep · peers by sector/industry